{"id":2974,"date":"2022-06-30T14:56:46","date_gmt":"2022-06-30T12:56:46","guid":{"rendered":"https:\/\/fci.health\/?page_id=2974"},"modified":"2024-04-19T10:25:11","modified_gmt":"2024-04-19T08:25:11","slug":"organoids","status":"publish","type":"page","link":"https:\/\/fci.health\/en\/organoids\/","title":{"rendered":"Organoid Biobank"},"content":{"rendered":"

[vc_row full_width=”stretch_row_content_no_spaces” dhsv_overflow=”vc-overflow-visible”][vc_column][dhsv_vc_header image=”2992″ headline=”Organoid Biobank” text=”Tumor organoids have been recognized as useful models for preclinical research. The biobank for human organoids enables FCI scientists to gain access to standardized protocols for cultivation of human organoids as well as to primary cell models to address their individual research questions.”][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/2″][\/vc_column][vc_column width=”1\/2″][dhsv_vc_textwithline linetype=”shortline” shortline=”true”]<\/p>\n

Introduction<\/h1>\n

Patient-derived tumor organoids (PDTOs)<\/span><\/i>\u00a0be generated from tissue samples after receiving informed consent. The technology is based on the expansion of primary cells under defined culturing conditions. Efficient protocols have been described for different types of cancer, such as colorectal, pancreatic and stomach cancer. PDTO biobanks recapitulate the molecular and phenotypic properties of the original tumor tissue. At the Georg-Speyer-Haus, we have established a biobank for colorectal cancer PDTOs from clinical samples from more than 250 patients at UCT Frankfurt. Molecular and histopathological analyses show a high degree of similarity to the original tumor tissue. Infrastructures for functional characterization have been established, including a platform for drug testing on PDTOs. As part of the FCI, the\u00a0Organoid Biobank<\/b>\u00a0is open to translational projects, and supports FCI researchers in developing their own PDTO models for different tumor entities. Existing models include tumors from ovarian cancer, brain metastases and head and neck tumors.<\/span><\/p>\n

<\/h2>\n

 <\/p>\n

Access<\/strong><\/h2>\n

Service available to<\/strong> – all entities, including for-profit organizations.<\/p>\n

Priority service for<\/strong> – no distinctions.[\/dhsv_vc_textwithline][\/vc_column][\/vc_row][vc_row][vc_column width=”2\/3″][vc_empty_space height=”85px”][vc_single_image image=”3029″ alignment=”left” css=”.vc_custom_1658312776203{margin-right: 50px !important;}”][\/vc_column][vc_column width=”1\/3″][vc_column_text]<\/p>\n


\nCore Services<\/strong><\/h2>\n